2-azetidin-3-yl-4-methyl-oxazole | 1228230-75-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-azetidin-3-yl-4-methyl-oxazole
• 英文别名: 2-(azetidin-3-yl)-4-methyl-1,3-oxazole
• CAS: 1228230-75-8
• 化学式: C₇H₁₀N₂O
• mdl: MFCD19227693
• 分子量: 138.169
• InChiKey: DCSOPGMCSTWSKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  10-chloro-5,6,8,9-tetrahydro-1,4,7,10a-tetraaza-cyclohepta[f]indene-7-carboxylic acid tert-butyl ester 、 2-azetidin-3-yl-4-methyl-oxazole 、 生成 10-[3-(4-methyl-oxazol-2-yl)-azetidin-1-yl]-6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene
  参考文献：
  名称：

  6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

  摘要：

  本发明涉及一种由式I定义的化合物，其中X、Y、W和R1至R4基团如权利要求1所定义，具有有价值的药理活性。特别地，这些化合物是5-HT2C受体激动剂，因此适用于治疗和预防可以通过抑制该受体受影响的代谢和中枢神经系统相关疾病。

  公开号：

  US09346816B2
• 作为产物：
  描述：

  3-(4-methyl-oxazol-2-yl)-azetidine-1-carboxylic acid benzyl ester 在 氢氧化钯 、 氮气 、 氢气 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 2-azetidin-3-yl-4-methyl-oxazole
  参考文献：
  名称：

  6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

  摘要：

  本发明涉及由公式I定义的化合物，其中X、Y、W和R1至R4的基团如权利要求书中所定义，具有有价值的药理活性。特别地，这些化合物是5-HT2C受体的激动剂，因此适用于治疗和预防可以受到该受体抑制影响的疾病，例如代谢和中枢神经系统相关的疾病。

  公开号：

  US20140066428A1

文献信息

• [EN] 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM<br/>[FR] DÉRIVÉS DE 6,7,8,9-TÉTRAHYDRO-5H-1,4,7,10A-TÉTRAAZA-CYCLOHEPT[F]INDÈNE, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS, LEUR UTILISATION ET PROCÉDÉS POUR PRÉPARER CEUX-CI
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010060952A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

  本发明涉及由式（I）定义的化合物，其中基团X、Y、W和R1至R4如权利要求1中所定义，具有有价值的药理活性。特别是这些化合物是5-HT2C受体的激动剂，因此适用于治疗和预防可以受到该受体抑制影响的疾病，如代谢和中枢神经系统相关疾病。
• 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
  申请人：Mueller Stephan-Georg

  公开号：US20120165304A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R 1 to R 4 are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

  本发明涉及由式(I)定义的化合物，其中X、Y、W和R1至R4基团如权利要求1中所定义，具有有价值的药理活性。特别地，这些化合物是5-HT2C受体激动剂，因此适用于治疗和预防可以受到该受体抑制影响的疾病，例如代谢和中枢神经系统相关疾病。
• 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2384328A1

  公开（公告）日：2011-11-09
• US9346816B2
  申请人：——

  公开号：US9346816B2

  公开（公告）日：2016-05-24
• 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
  申请人：Mueller Stephan-Georg

  公开号：US09346816B2

  公开（公告）日：2016-05-24

  The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

  本发明涉及一种由式I定义的化合物，其中X、Y、W和R1至R4基团如权利要求1所定义，具有有价值的药理活性。特别地，这些化合物是5-HT2C受体激动剂，因此适用于治疗和预防可以通过抑制该受体受影响的代谢和中枢神经系统相关疾病。